Joan Ripley Coates

Dr. Joan Ripley Coates

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
JCJoan Ripley Coates
Joan Ripley Coates
NJNick D Jeffery
Nick D Jeffery

1 September 2010 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
JCJoan Ripley Coates
Joan Ripley Coates
FWFred A. Wininger
Fred A. Wininger

1 January 2007 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
JCJoan Ripley Coates
Joan Ripley Coates
GBGeorgina Barone
Georgina Barone
CDCurtis W. Dewey
Curtis W. Dewey
CVChristina L. Vitale
Christina L. Vitale
NHNicole M. Holloway‐Azene
Nicole M. Holloway‐Azene
JSJohn K. Sessions
John K. Sessions

1 January 2007 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
PDF file
JCJoan Ripley Coates
Joan Ripley Coates
PMPhilip A. March
Philip A. March
MOMichael Oglesbee
Michael Oglesbee
CRCraig Ruaux
Craig Ruaux
NONatasha Olby
Natasha Olby
DWDavid A. Williams
David A. Williams

1 November 2004 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
JCJoan Ripley Coates
Joan Ripley Coates
DODennis P. O'BRien
Dennis P. O'BRien

1 January 2007 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Closed access
JCJoan Ripley Coates
Joan Ripley Coates
GBGeorgina Barone
Georgina Barone
CDCurtis W. Dewey
Curtis W. Dewey
CVChristina L. Vitale
Christina L. Vitale
NHNicole M. Holloway-Azene
Nicole M. Holloway-Azene
JSJohn K. Sessions
John K. Sessions
Granulomatous meningoencephalomyelitis (GME) is an idiopathic inflammatory disease of the central nervous system. Remission often is short-lived in dogs treated with glucocorticoids. Procarbazine is T cell-specific and crosses the blood-brain barrier. Dogs with presumptive antemortem diagnosis of GME given procarbazine as adjunctive therapy to prednisone will have improved long-term outcome compared with dogs given no treatment or glucocorticoids alone. Two groups were studied: (1) Dogs with presumptive antemortem diagnosis of GME treated with procarbazine and prednisone (n = 21); (2) Dogs that had a histologic diagnosis of GME at postmortem examination and received no treatment (n = 11). Dogs with presumptive GME treated with procarbazine were identified retrospectively from medical records of 2 veterinary referral hospitals. Selection criteria required all dogs have a neurologic examination, blood work, cerebrospinal fluid analysis, and brain imaging (MRI or CT). Median survival time for all dogs studied was 5.0 months. Median survival time for dogs treated with procarbazine was 14.0 months and for untreated dogs, 0.73 months. Treatment with procarbazine was significantly correlated with survival time (P < .001). Procarbazine was the only independent predictor of survival. Prednisone was reduced in dosage or discontinued in 17 dogs. Adverse reactions to procarbazine therapy included myelosuppression in 7 dogs and hemorrhagic gastroenteritis in 3 dogs. These data suggest that procarbazine treatment of presumptive GME may result in greater improved long-term outcome than has been previously reported for glucocorticoid treatment alone and may complement other immunomodulatory therapies. Procarbazine-treated dogs must be monitored for adverse reactions.